One of the Largest Comprehensive PediatricHematology/Oncology Programs in the U.S.

Over the past decade, the internationally recognized physicians and scientists at Children's Mercy Hospitals and Clinics have quietly turned Kansas City into a major hub for pediatric oncology research and treatment. More>>

Recognized for Outstanding Achievement by the AmericanCollege of Surgeons Commission on Cancer

In 2006 and again in 2009, Children's Mercy was the only pediatric hospital in the nation to receive the Outstanding Achievement Award from the American College of Surgeons Commission on Cancer. More>>

Exemplary Case Management Ensures Consistent Quality ofCare 

The foundation of the Hematology, Oncology and Bone Marrow Transplantation Program at Children's Mercy is the staff's commitment to extraordinary, individualized patient care. That's why every patient is followed throughout treatment by a specific team comprised of a physician, nurse practitioner and social worker. More>>

Improving Chemotherapy Dosing

For more than a decade, Children's Mercy has been an international leader in the field of pediatric clinical pharmacology. Our doctors and research scientists are at the forefront in the study of medicines and how they work in children. More>>

Developing a World-Class Experimental TherapeuticsProgram

Children's Mercy operates the largest pediatric clinical pharmacology program in North America. Building on our internationally recognized strength in clinical pharmacology and national reputation and stature within the Children's Oncology Group, Children's Mercy is developing an integrated Phase I Experimental Therapeutics Program. More>>

Promoting Resilience in Stem Cell TransplantPatients

In collaboration with colleagues across the country, Kristin Stegenga, RN, PhD, is studying the symptoms that adolescents and young adults experience while undergoing stem cell transplant (SCT). More>>

Clinical Pharmacology Provides Core Expertise forConsortia Seeking to Reformulate Cancer Drugs forChildren

Two years ago, Kathleen A. Neville, MD, MS, was asked to assume the job of Director of the Experimental Therapeutics in Pediatric Cancer Program (ETPC) at Children's Mercy. The goal was to give children with refractory cancer a local option to pursue treatment with early phase cancer drugs. More>>

Alleviating Side Effects of Bone Marrow Transplants withPhotopheresis Therapy

For the past decade, Children's Mercy Hospital and Clinics' Jignesh Dalal, MD, has worked to perfect a widely used therapy that reduces bone marrow rejection, making it safe for children. More>>

Research Seeks Understanding of the Role of MLL Gene inInfant Leukemia

The mixed lineage leukemia gene (MLL) is important in human development. It is also a major contributor to the development of infant leukemia. A physician researcher at Children's Mercy wants to know why. More>>

Leadership Roles Keep Children's Mercy at Forefront ofPediatric Oncology

"Children's Mercy Hospital sees 180 new children with cancer a year. As one of the larger Children's Oncology Group (COG) cancer centers, we have available for our patients 80 to 100 trials open for children, not only through COG but also Phase I and transplant consortia," says Alan Gamis, MD, Associate Division Director of the Section of Oncology at Children's Mercy. More>>

Our Approach to Refractory Drug Studies

Expertise in Pediatric Clinical Pharmacology positions Children's Mercy as a leader in refractory drug studies. More>>

AYA Program Focuses on Improving Outcomes forAdolescents and Adults

Every year about 26,000 patients between the ages of 15 and 29 are diagnosed with cancer in the United States and Canada. Unfortunately, outcomes for patients in this age range are not as good as younger patients with the same diagnoses. More>>

New Clinical Trial Uses Gene Therapy AgainstNeuroblastoma

With research that will make Children's Mercy a trailblazer in neuroblastoma treatment, Doug Myers, MD, has launched a clinical trial exploring ways to use genetic alteration to redirect virus-fighting T-cells to attack specific tumors. More>>